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Fig. 1. High magnification electron micrographs of rat hepatic endothelial fenestrae. (A) Transmission electron microscopy image of sectioned
hepatic endothelial cells in situ, showing the fenestrated, processes (arrow) and the histologic relationship with the numerous microvillous processes
of the liver parenchymal cells situated in the space of Disse. (B) Scanning electron micrograph of the fenestrated cytoplasm of hepatic endothelial
cells in vitro. Notice the fenestrae (arrow) on the cell surface. (C) Whole-mount transmission electron micrograph of the fenestrated cytoplasm
(arrow) of a hepatic endothelial cell cultured on transmission electron microscopy grids, disclosing the process of fenestrae formation. Note the
area of intermediated density from which rows of fenestrae with increasing diameter are radiating into the surrounding cytoplasm. Scale bars,
200 mm.
endothelium were completely devoid of caveolin-1, sim-
ilar to the report by Esser et al [9] for the choroid plexus
endothelium. Now, our experiments leave open the
possibility that fenestrae in other vascular beds could
represent fused caveolae, and that caveolar precursor
vesicles lacking caveolin-1 could fuse to form fenes-
trae. But if caveolae are defined as specialized plasma
membrane invaginations stabilized by caveolins, then our
findings in caveolin-deficient mice seem to prove that fen-
estrae in glomerular endothelium cannot represent fused
caveolae.
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Immunosuppressive and
calcimimetic drug-drug
interactions
To the Editor: Drug-drug interactions (DDIs) are an
important cause of adverse drug reactions. It has been es-
timated that approximately 5% of prescribing errors [1]
or of adverse drug reactions [2] are caused by DDIs in
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Table 1. Calcimimetic and immunosuppressive drug-drug
interactions through cytochrome P450 (CYP) and transporters
Metabolic pathway
CYP
Inductor or
Drugs substrate Inhibitor Transporters
Calcimimetic drugs
Cinacalcet 1A2, 3A4 2D6 ?
Immunosuppressive drugs
P-gp, MRP,
GCs 3A4 OATP
AZA
MMF 3A4
P-gp OATP
CsA 3A4 MRP2
FK 3A4 P-gp OATP
Siro 3A4 P-gp OATP
Abbreviations are: AZA, azathioprine; CsA, cyclosporine; FK, tacrolimus;
GCs, glucocorticoids; MMF, mycophenolate mofetil; Siro, sirolimus, Pgp,
glycoprotein, OATP, hepatocyte-specific organic anion uptake transporter.
hospitalised patients. Mechanisms of drug-drug interac-
tion include competitive interaction between two drugs
that are metabolized via the same enzyme system [for
example, cytochrome P450 (CYP)] or a competition for
the same active transport system, such as P-glycoprotein
(P-gp) or organic anion transporter peptide (OATP).
Cinacalcet is becoming the cornerstone of the
end-stage renal disease (ESRD) therapy to reduce
parathyroid hormone levels in patients with secondary
hyperparathyroidism who are receiving hemodialysis,
and to ameliorate disturbances in serum calcium and
phosphorus [3]. Indeed, more ESRD patients may un-
dergo renal transplantation with this medication.
Although immunosuppression is required for graft
maintenance, it is unknown how and to what extent the
antirejection therapies will interact with the calcimimetic
medication. Cinacalcet is metabolized by multiple en-
zymes, primarily the CYP3A4, CYP2D6, and CYP1A2.
In addition, they may also inhibit the 2D6 enzyme’s ac-
tivity [4]. Since cyclosporine, tacrolimus, and sirolimus,
the most popular immunosuppressive therapies, share the
same metabolic pathway [5], significant drug-drug inter-
actions may occur when these medications are given con-
comitantly. Table 1 summarizes those potential DDIs.
Physicians should be aware for the potential drug-drug
interactions between calcimimetic and immunosuppres-
sive agents.
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